Last updated on May 2017

A Phase I Study With Lymfactin in the Treatment of Patients With Secondary Lymphedema


Brief description of study

Indicated for the Treatment of Secondary Lymphedema Associated with the Treatment of Breast Cancer. Primary objective is to evaluate the safety and tolerability of a single dose of Lymfactin® in patients with secondary lymphedema associated with the treatment of breast cancer.

Detailed Study Description

This is an open label, multi-center, uncontrolled first in human trial that uses a standard 3 + 3 dose escalation scheme. Lymfactin® will be administered as a single dose by ex vivo perinodal injection into the fat pad of a flap of tissue containing lymph nodes from the abdominal wall. This flap of tissue will then be surgically implanted into the axillary region of the affected arm. This treatment with Lymfactin® may be performed in conjunction with or without breast reconstruction surgery. Up to two dose cohorts are planned to be included. Each dose of Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL: - Cohort 1: Lymfactin® [1 x 10E10 vp] - Cohort 2: Lymfactin® [1 x 10E11 vp] Should the dose escalation go up to Cohort 2 with initiation of a subsequent Extension Cohort a total of 15 - 21 patients may be treated in this study.

Clinical Study Identifier: NCT02994771

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Sinikka Suominen

Toeoeloe Hospital, Department of Plastic Surgery
Helsinki, Finland
  Connect »

Ilkka Kaartinen

Tampere University Hospital, Department of Plastic Surgery
Tampere, Finland
  Connect »

Erkki Suominen

Turku University Hospital, Department of Plastic Surgery
Turku, Finland
  Connect »